Published in Cancer Biol Ther on December 07, 2008
The molecular pathogenesis of osteosarcoma: a review. Sarcoma (2011) 1.91
Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J (2009) 0.97
Imaging pediatric bone sarcomas. Radiol Clin North Am (2011) 0.90
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat Oncol (2012) 0.81
In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth. Comput Math Methods Med (2013) 0.75
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging (2003) 8.56
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A (1996) 5.93
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
PET imaging of osteosarcoma. J Nucl Med (2003) 1.95
Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol (1999) 1.58
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med (1999) 1.53
Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med (2001) 1.47
On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer (1997) 1.42
C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology (1998) 1.33
The contribution of PET/CT to improved patient management. Br J Radiol (2006) 1.19
Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol (1994) 1.08
Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr (1993) 1.07
A recent application of fluoro-18-deoxyglucose positron emission tomography, treatment monitoring with a mammalian target of rapamycin inhibitor: an example of a patient with a desmoplastic small round cell tumor. Hell J Nucl Med (2007) 1.00
Role of PET/PET-CT in the management of sarcomas. Expert Rev Anticancer Ther (2006) 0.93
Amplification and rearrangement of c-myc in radiation-induced murine osteosarcomas. Cancer Res (1990) 0.87
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging (2003) 8.56
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer (2010) 3.64
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel (2006) 3.27
Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A (2010) 2.89
Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med (2012) 2.88
Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med (2009) 2.66
Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat Methods (2007) 2.64
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med (2009) 2.31
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A (2002) 2.01
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
Design and evaluation of a variable aperture collimator for conformal radiotherapy of small animals using a microCT scanner. Med Phys (2007) 1.90
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Radiation-luminescence-excited quantum dots for in vivo multiplexed optical imaging. Small (2010) 1.87
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res (2005) 1.85
Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett (2008) 1.85
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood (2002) 1.84
Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol (2006) 1.82
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev (2010) 1.81
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res (2007) 1.74
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
Uptake kinetics and biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging. Eur J Nucl Med Mol Imaging (2008) 1.64
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging (2011) 1.63
Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med (2008) 1.63
Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. Mol Ther (2003) 1.62
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res (2008) 1.58
MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res (2006) 1.57
90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med (2008) 1.56
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo. Stem Cells (2007) 1.54
Design, synthesis, and imaging of an activatable photoacoustic probe. J Am Chem Soc (2010) 1.52
Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J (2005) 1.52
Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med (2007) 1.46
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One (2008) 1.46
Crystal structures of the luciferase and green fluorescent protein from Renilla reniformis. J Mol Biol (2007) 1.44
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res (2009) 1.38
Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett (2012) 1.37
Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol (2012) 1.37
Noninvasive imaging of protein-protein interactions from live cells and living subjects using bioluminescence resonance energy transfer. FASEB J (2005) 1.36
Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation (2004) 1.33
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res (2011) 1.32
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. Int J Radiat Oncol Biol Phys (2010) 1.29
Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol Med (2010) 1.28
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A (2003) 1.27
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood (2007) 1.27
Synthesis and radioluminescence of PEGylated Eu(3+) -doped nanophosphors as bioimaging probes. Adv Mater (2011) 1.26
An improved bioluminescence resonance energy transfer strategy for imaging intracellular events in single cells and living subjects. Cancer Res (2007) 1.25
Molecular imaging of cardiovascular gene products. J Nucl Cardiol (2004) 1.25
BRET3: a red-shifted bioluminescence resonance energy transfer (BRET)-based integrated platform for imaging protein-protein interactions from single live cells and living animals. FASEB J (2009) 1.25
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A (2009) 1.25
Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet (2008) 1.23
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med (2013) 1.22
Bioluminescent monitoring of islet graft survival after transplantation. Mol Ther (2004) 1.21
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res (2011) 1.20
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.19
Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol (2004) 1.17
Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med (2007) 1.16
Photoacoustic ocular imaging. Opt Lett (2010) 1.16
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet (2012) 1.15
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A (2011) 1.13
SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One (2012) 1.13
Controlling the selection stringency of phage display using a microfluidic device. Lab Chip (2009) 1.12
Image-guided cardiac cell delivery using high-resolution small-animal ultrasound. Mol Ther (2005) 1.11
Conditionally MYC: insights from novel transgenic models. Cancer Lett (2004) 1.10
Monitoring caspase-3 activation with a multimodality imaging sensor in living subjects. Clin Cancer Res (2008) 1.10
Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med (2006) 1.10
Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem (2005) 1.10
Ovarian cancer early detection claims are biased. Clin Cancer Res (2008) 1.10
A red-shifted Renilla luciferase for transient reporter-gene expression. Nat Methods (2010) 1.10
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol (2009) 1.10
Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J Clin Invest (2011) 1.10
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther (2009) 1.09
Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med (2008) 1.09
The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am J Pathol (2009) 1.08
Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res (2005) 1.07
Molecular photoacoustic imaging of follicular thyroid carcinoma. Clin Cancer Res (2013) 1.06
Dynamic visualization of RGD-quantum dot binding to tumor neovasculature and extravasation in multiple living mouse models using intravital microscopy. Small (2010) 1.05
Fluorescent fructose derivatives for imaging breast cancer cells. Bioconjug Chem (2007) 1.05
Endoscopic imaging of Cerenkov luminescence. Biomed Opt Express (2012) 1.05
Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad Sci U S A (2006) 1.04
Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One (2009) 1.04
Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res (2008) 1.03
Molecular imaging applications for immunology. Clin Immunol (2004) 1.02